Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 4
2018 6
2019 32
2020 42
2021 22
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31435660

101 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM. Aguilar EJ, et al. Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288. Ann Oncol. 2019. PMID: 31435660 Free article.
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R, Kanazu M, Kurebe H, Mori M, Fujimoto D, Taniguchi Y, Suzuki H, Hirano K, Yokoyama T, Morita M, Fukuda Y, Uchida J, Makio T, Tamiya M. Edahiro R, et al. PLoS One. 2019 Jul 31;14(7):e0220570. doi: 10.1371/journal.pone.0220570. eCollection 2019. PLoS One. 2019. PMID: 31365588 Free PMC article.
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H, Fukuda Y, Yokoyama T, Kominami R, Fujimoto D, Hosoya K, Suzuki H, Hirashima T, Kanazu M, Sawa N, Uchida J, Morita M, Makio T, Hara S, Kumagai T. Kawachi H, et al. Invest New Drugs. 2020 Feb;38(1):211-218. doi: 10.1007/s10637-019-00882-5. Epub 2019 Nov 30. Invest New Drugs. 2020. PMID: 31784866
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M, Nosaki K, Takahashi T, Nakagawa K, Aoe K, Kurata T, Sekine A, Horiike A, Fukuhara T, Sugawara S, Umemura S, Saka H, Okamoto I, Yamamoto N, Sakai H, Kishi K, Katakami N, Horinouchi H, Hida T, Okamoto H, Atagi S, Ohira T, Han SR, Noguchi K, Ebiana V, Hotta K. Satouchi M, et al. Cancer Sci. 2020 Dec;111(12):4480-4489. doi: 10.1111/cas.14647. Epub 2020 Oct 16. Cancer Sci. 2020. PMID: 32926507 Free PMC article. Retracted. Clinical Trial.
101 results